[PAR] [TLE] Losmapimod [SEP] Losmapimod (GW856553X) is a drug developed by GlaxoSmithKline which acts as a selective inhibitor of the enzyme family known as p38 mitogen-activated protein kinases. [PAR] [TLE] GlaxoSmithKline [SEP] The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index.  As of August 2016 it had a market capitalisation of £81 billion (around $107 billion), the fourth largest on the London Stock Exchange.  It has a secondary listing on the New York Stock Exchange.
[PAR] [TLE] Losmapimod [ SEP ] Losmapimod ( GW856553X ) is a drug developed by GlaxoSmithKline which acts as a selective inhibitor of the enzyme family known as p38 mitogen - activated protein kinases . [PAR] [TLE] GlaxoSmithKline [ SEP ] The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index . As of August 2016 it had a market capitalisation of £ 81 billion ( around $ 107 billion ) , the fourth largest on the London Stock Exchange . It has a secondary listing on the New York Stock Exchange .
As of August 2016, what was the market capitalisation of the company that developed the drug Losmapimod?
As of August 2016 , what was the market capitalisation of the company that developed the drug Losmapimod ?
£81 billion
£81 billion